XTX Topco Ltd Raises Stake in Pacific Biosciences of California, Inc. $PACB

XTX Topco Ltd increased its stake in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) by 95.5% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 954,596 shares of the biotechnology company’s stock after buying an additional 466,359 shares during the quarter. XTX Topco Ltd’s holdings in Pacific Biosciences of California were worth $1,184,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of PACB. Vanguard Group Inc. increased its stake in shares of Pacific Biosciences of California by 6.8% during the 1st quarter. Vanguard Group Inc. now owns 16,263,464 shares of the biotechnology company’s stock worth $19,191,000 after purchasing an additional 1,036,606 shares during the last quarter. Koss Olinger Consulting LLC grew its holdings in Pacific Biosciences of California by 50.0% during the first quarter. Koss Olinger Consulting LLC now owns 3,000,000 shares of the biotechnology company’s stock valued at $3,540,000 after purchasing an additional 1,000,000 shares during the period. Vestmark Advisory Solutions Inc. increased its position in Pacific Biosciences of California by 89.9% in the second quarter. Vestmark Advisory Solutions Inc. now owns 1,294,186 shares of the biotechnology company’s stock worth $1,605,000 after buying an additional 612,760 shares during the last quarter. Edmond DE Rothschild Holding S.A. raised its stake in shares of Pacific Biosciences of California by 2.4% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 21,855,180 shares of the biotechnology company’s stock valued at $25,789,000 after buying an additional 508,700 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd raised its stake in shares of Pacific Biosciences of California by 148.1% in the second quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 789,271 shares of the biotechnology company’s stock valued at $979,000 after buying an additional 471,101 shares during the period.

Pacific Biosciences of California Stock Performance

Shares of PACB opened at $2.31 on Friday. Pacific Biosciences of California, Inc. has a 12-month low of $0.85 and a 12-month high of $2.72. The company has a current ratio of 6.92, a quick ratio of 6.02 and a debt-to-equity ratio of 10.51. The company has a market cap of $697.41 million, a PE ratio of -1.01 and a beta of 2.30. The stock has a 50-day moving average price of $1.77 and a 200-day moving average price of $1.45.

Pacific Biosciences of California (NASDAQ:PACB) last announced its earnings results on Wednesday, March 29th. The biotechnology company reported ($0.23) earnings per share for the quarter. Pacific Biosciences of California had a negative net margin of 336.40% and a negative return on equity of 66.75%. The company had revenue of $3.34 million during the quarter. As a group, equities analysts forecast that Pacific Biosciences of California, Inc. will post -0.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on PACB. Stephens increased their price target on Pacific Biosciences of California from $1.80 to $2.00 and gave the stock an “overweight” rating in a research note on Monday, November 10th. Wall Street Zen raised shares of Pacific Biosciences of California from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Piper Sandler lifted their target price on shares of Pacific Biosciences of California from $1.50 to $2.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 11th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Pacific Biosciences of California in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $2.00.

Pacific Biosciences of California Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.